Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 6Active not recruiting 3Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 8NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Cisplatin 14Radiotherapy 13Oxaliplatin 8Fluorouracil 7Gemcitabine 6Drug Therapy 6Leucovorin 5Doxorubicin 5Cytarabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5durvalumab 4Paclitaxel 4Etoposide 4Docetaxel 4Chemotherapy, Adjuvant 4Biological Therapy 4bicalutamide 3Rituximab 3Radiotherapy, Intensity-Modulated 3Polymerase Chain Reaction 3Platinum 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Gene Expression Profiling 3Dexamethasone 3Bortezomib 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × dexamethasone acetate × Clear all
NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡